Telavancin

Telavancin
Clinical data
Trade names	Vibativ
AHFS/Drugs.com	Monograph
MedlinePlus	a610004
License data	EU EMA: by INN; US FDA: Telavancin;
Routes of; administration	intravenous
ATC code	J01XA03 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	N/A
Protein binding	90%, mostly to albumin
Elimination half-life	9 hours
Excretion	76% in urine, <1% in feces
Identifiers
	IUPAC name (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-5,15-dichloro-48-{[2-O-(3-{[2-(decylamino)ethyl]amino}-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-36-{[(phosphonomethyl)amino]methyl}-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid;
CAS Number	372151-71-8 ;
PubChem CID	3081362;
DrugBank	DB06402;
ChemSpider	2338980 ;
UNII	XK134822Z0;
ChEBI	CHEBI:71229 ;
ChEMBL	ChEMBL507870 ;
CompTox Dashboard (EPA)	DTXSID10873383 ;
ECHA InfoCard	100.106.567
Chemical and physical data
Formula	C80H106Cl2N11O27P
Molar mass	1755.65 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C;
	InChI InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1 ; Key:ONUMZHGUFYIKPM-MXNFEBESSA-N ;
	(what is this?) (verify)

Telavancin (trade name Vibativ by Cumberland Pharmaceuticals) is a bactericidal lipoglycopeptide for use in MRSA or other Gram-positive infections. Telavancin is a semi-synthetic derivative of vancomycin.^[1]^[2]

The FDA approved the drug in September 2009 for complicated skin and skin structure infections (cSSSI),^[3] and in June 2013 for hospital-acquired and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus.^[4]

^ Astellas, Inc. VIBATIV prescribing information, 9/2009.
^ Cite error: The named reference HIG2005 was invoked but never defined (see the help page).
^ Cite error: The named reference TA-FDA was invoked but never defined (see the help page).
^ "FDA approves Vibativ for hospitalized patients with bacterial pneumonia". Food and Drug Administration. Archived from the original on 2013-08-31. Retrieved 2013-08-19.

[1] Astellas, Inc. VIBATIV prescribing information, 9/2009.

[HIG2005-2] Cite error: The named reference HIG2005 was invoked but never defined (see the help page).

[TA-FDA-3] Cite error: The named reference TA-FDA was invoked but never defined (see the help page).

[4] "FDA approves Vibativ for hospitalized patients with bacterial pneumonia". Food and Drug Administration. Archived from the original on 2013-08-31. Retrieved 2013-08-19.

[1]

[2]

[3]

[4]